"Geron and J&J began treating patients last September in an open-label study with two imetelstat dosage arms.(IMbark) Success here probably wouldn't be enough to file an application, but it could do wonders for Geron's stock, and soon. In the second half of the year, then again in 2017, J&J is expected to check in on how things are going. If at least one of the dosage arms shows acceptable levels of safety and efficacy, J&J probably will probably take the drug through phase 3 and into commercial stages, triggering some hefty milestone payments for Geron."
I beg to differ with his comment 'Success here probably wouldn't be enough to file an application' as this would place IMET in the BAT(best available therapy) status category resulting in an expedited FDA approval designation. It's all Janssen needs for a quick approval. Also noteworthy wrt Imerge, it has already moved beyond phase II of its II/III phase part as indicated by the govt trial registry, noting things must be moving along well.
Apart from that I thought that Cory's article was one of the better ones coming out of the Motley Fool and summed up with clarity the potential here. He also mentioned "However, if data thrown off from the IMbark or IMerge trials boosts the stock, I'm worried the company will get ahead of itself and raise equity to acquire another candidate. (Hear that Chippy...no one wants another shelf exercised purchase)
Instead, what I'd like to see is for Geron to stay patient, let the J&J collaboration play out, and then increase its pipeline with positive cash flows, not equity. The temptation to raise equity will be hard to resist if the price spikes. However, remaining prudent will allow shareholders a larger slice of profits and increase the stock price over the long run." If only our CEO could deliver such forward looking guidance. Hmmmm.......SIGH
Cory for Prez maybe?
to rocky squirrel, from one rodent to another had you followed "Sdrawkcabeman, Irishtrader52, Earfool, Biopearl, Tazmatic and a few others that have what it takes to write an informed or at least, interesting to read post." and based your investment DD on that, buying into GERN's chipmunk's pension plan would have ruined your financial portfolio as it has mine. Nothing Chippy has delivered, even the Jansson deal (which barely got a SP boost) has moved this SP up to where it should be based on Imet's development and market potential. The Mayo under T-fairy was great in developing the drug in it's early stages, Janssen's 2 new world trials for establishing IMET's viability and eventual expedited approval could never have been done in house by GERN. This being said, although the Chipper did get the deal down, which I give him credit for and should be adequately compensated for when the time comes, he has deliberately sandbagged ever since and has caused undue selling pressure by ;
#1. his publicly stated acquisition intentions all through 2015 and the Fidelity shelf registration last Sept. which really killed the SP.
#2. his delayed booking the $35mil by a year
#3. he has yet to promote the drug within safe harbor guidelines for market valuation potentials supporting investment DD
#4. he has not yet PR'd EU ODD designation for IMET ( a reportable event)
#5. he needs to clarify the milestone payment requirement payments for the new Janssen trials rather than this board trying to decipher the terms of that rather lengthy collaborative contract with them. The market hates uncertainty and this guessing has added to it.
#6. he needs to stop going from racing car management analogies to sticking to the knitting as referencing what he is doing with the large sum of money I have entrusted him with and stopped feeding my shares to the sharks.
"Maintenance imetelstat failed to improve PFS in advanced NSCLC patients responding to first-line therapy. There was a trend toward a improvement in median PFS and OS in patients with short TL. Short TL as a predictive biomarker" if these were the (non-significant) trial results why would GERN want to be revisiting solid tumor trials again? They failed with earlier paclitaxel combo breast cancer trials(2012) as with earlier lung cancer trials; " The Company also announced that it is continuing its randomized Phase 2 study of imetelstat in advanced non-small cell lung cancer (NSCLC). However, although a separate interim analysis of the NSCLC study suggested a modest trend of efficacy in favor of the imetelstat arm, the pre-specified success criteria in this trial are unlikely to be met, and, as a consequence, it is doubtful that Geron will take imetelstat forward into Phase 3 development for NSCLC."
Bringing up failed trial data Anne does not help SP.
he`s part of the wider cancer plaguing this nation
average US CEO compensation was 30x that of average employee`s in 1988
today that`s grown to 300x that of average employee. This when real wages have only increased by .025 in the same time frame. Wholesale theft of Mainstreet by management enabled by State Street and delivered to you by Wall street.
looks like Ho Cheng's argument is a floater left over from the first time his interpretation on telomerase inhibitors got flushed down the toilet 13 tears ago..
off the island. Irish is good at that kinda stuff. She never held very high regards for our used car salesman always praising T Fairy never dah chipmunk.
their strategy this spring is to have every disgruntled long sell so Chippy wont be proxy voted off the island. As it stands very few long term investors are left standing.
self fulfilling prophecy; if Trump becomes president we will experience a nuclear winter.
"Fiduciary obligations exist to ensure that those who manage other people’s money act responsibly in the interests of investors, rather than serving their own interests. The nature of the fiduciary relationship means that a fiduciary is expected to be loyal to the person to whom he or she owes the duty. In particular, fiduciaries should not put their personal interests before the duty, should avoid conflicts to the extent possible (and, if they cannot be avoided, conflicts should be minimized, disclosed and carefully managed to prevent any breaches of loyalty obligations), should ensure that their fiduciary duty does not conflict with other legal duties or their own interests, and should not profit unreasonably from their fiduciary position.
Fiduciary duties are generally seen as requiring a higher standard of performance than those that are generally imposed in contracts."
....has this CEO met with his fiduciary responsibility? Don't tell me or splash your vote all over this board just vote on the next proxy.
the only duck quacking is Joko and he works for Affleck. Do you honestly believe 1-2 years more to seriously decide if GERN's a winner or not? WRT to all three on going current trials two of which are phase 2(IMBark NCT02426086 & MF NCT01731951) and one well into phase 3 (Emerge, NCT02598661) not mention all the 6 years of data already collected on IMET me thinks our capricious CEO is bagging our timelines for some other nefarious cause.
HMMMMMMMMMMMMM at half the value of Proteolix, GERN;s current market cap at $452 could be bought out at 2x current value by Janssen making it closer to $5.72. Almost dead on with Chippy's option's price of $5.80
thumbs mean nothing on this manipulated stock board. i`m pretty sure Joko`s responsible for at least 10 aliases on only one hand..
Irish had as many as 100`s a few years ago,. Where have all those thumbs gone? SP is down by $3 since Jan 2014 and Dec 2013
Gern's compensation committee awarded themselves a 3% package increase this year and yet shareholders took a 4% hit o their share price today following an investor's presentation; 50% off the 52 week high. Something is wrong with this picture. Curious critters want to know why?
"As for ET, John on a CC mention that it was not economical to go after ET because there to many competition for ET and a faster way for approval was to go after MF as an orphan drug" ...actually the deal with the FDA hold being lifted was that GERN would not pursue ET designations as there is a greater unmet medical need for a new product than is the case for diseases such as ET, for which survival is minimally affected by the disease. Probably an INCY clause in place. Subsequently Jansen's first new trial was an IMET's high risk MF patients trial previously treated with Jakafi; a major game changer for this space and IMET directly comparing both drug results. If data supports Mayo's MF results, Imet will become the standard for MF treatment under BAT. (7 months of data collected so far from Oct 2015 1ST infusion)
rokky44, glad your happy with a 50% SP haircut based mainly on Chippy65's failed acquisition stunt. I think the market believes he will still pull it off regardless of publicly stating he would refrain till Imet was further along the approval path during the Dec CC. You are a stupid investor if you are happy to what has happened unless you're a paid shill from Fidelity ad shorting the stock.